Amgen (AMGN) Stock Dividend Data
$101.50 +2.42 (2.38%)
Volume: 3,328,900 (Avg: 3,429,335)
Quote time: Jun 18, 2013 7:58pm
|52-week Low / High||70.88 / 114.95|
|% Off 52-week High||-11.70%|
|Day's Range||99.07 - 102.29|
|DARS™ Rating||Sign Up for Ratings|
|Amount||Ex-Dividend Date||Record Date||Pay Date||Declare Date||Qualified? [?]||Type|
Dividend.com DARS™ Ratings Breakdown for AMGN
Only for Premium Members
If you were a Dividend.com Premium member, you would be seeing detailed DARS™ Dividend Stock Ratings information for Amgen (AMGN) in this space, including whether we think your should Buy, Hold, or Sell this stock.
Sign up for Dividend.com Premium today to gain access to ratings on nearly 1,600 dividend-paying stocks, exclusive members-only articles, historical dividend information, and more!
Recent Headlines for AMGN
Jun 13, 2013
Jun 12, 2013
Jun 12, 2013
May 31, 2013
May 29, 2013
May 20, 2013
May 1, 2013
Apr 30, 2013
Apr 24, 2013
Apr 24, 2013
Amgen (AMGN) Profile
Amgen (AMGN) - this company discovers, develops, manufactures, and markets human therapeutics based on advances in cellular and molecular biology for grievous illnesses primarily in the United States, Europe, and Canada. The company markets recombinant protein therapeutics in supportive cancer care, nephrology, and inflammation. Its principal products include Aranesp and EPOGEN erythropoietic-stimulating agents that stimulate the production of red blood cells; Neulasta and NEUPOGEN to stimulate the production of neutrophils, which is a type of white blood cell that helps the body to fight infections; and Enbrel, an inhibitor of tumor necrosis factor that plays a role in the body's response to inflammatory diseases. The company also markets other products comprising Sensipar/Mimpara, a small molecule calcimimetic that lowers serum calcium levels; Vectibix, a monoclonal antibody that binds specifically to the epidermal growth factor receptor; and Nplate, a thrombopoietin (TPO) receptor agonist that mimics endogenous TPO, the primary driver of platelet production. In addition, it provides Denosumab, a human monoclonal antibody that targets RANKL, an essential regulator of osteoclasts. Further, the company offers product candidates in mid-to-late stage development in a variety of therapeutic areas, including oncology, hematology, inflammation, bone, nephrology, cardiovascular, and general medicine consisting of neurology. It markets its products to healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies; consumers; and wholesale distributors of pharmaceutical products. The company has various collaborative arrangements with Pfizer Inc.; GlaxoSmithKline plc; Takeda Pharmaceutical Company Limited; Daiichi Sankyo Company, Limited; Array BioPharma Inc.; Kyowa Hakko Kirin Co. Ltd.; and Cytokinetics, Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
Historical Dividend Data for Amgen (AMGN)
Don't Miss Out!
If you were a Dividend.com Premium member, you would be seeing complete historical dividend data for AMGN, including payout amounts and dates! Sign up for Dividend.com Premium today to gain access to ratings on nearly 1,600 dividend-paying stocks, exclusive members-only articles, historical dividend data, and much more!
If you are already a Dividend.com Premium subscriber, please login here.
* Stock prices are subject to a 15-minute delay.
** Under no circumstances does the information on this website represent a recommendation to buy or sell stocks. The author is not registered as an investment adviser. The author may or may not hold positions in the securities mentioned in this article or video. The author relies upon the "publisher's exclusion" from the definition of "investment adviser" as provided under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws.
*** All dividend payout and date information on this website is for information purposes only. We do not guarantee the accuracy of any dividend dates or payout amounts. Always check with your broker first before purchasing any security.
FREE Dividend Stock Newsletter
Get the Dividend.com email newsletter to receive:
- A free copy of our acclaimed report, 5 Rules of Winning Dividend Stock Investing
- Free daily investing tips and picks from Dividend.com CEO Paul Rubillo
- Tons of great market analysis and recommendations